



First US patent for Sofra™ technology platform

Highlights

- **First-tier patent for innovative cancer research granted**
- **Future-proofs development pipeline**
- **Growing US\$36 billion immuno-oncology market**

Sydney, 22 October 2025: Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce it has been granted its first patent for the [Sofra™](#) technology platform.

The patent was granted by the United States Patent and Trademark Office and relates to how Noxopharm's innovative immune-modulatory oligonucleotides could harness the immune system for the treatment of certain types of cancer.

This is a 'first-tier' composition of matter patent, meaning that it protects the structure of Noxopharm's assets for the development of novel pharmaceutical compounds.

In essence, the patent protects the commercial value of cancer-related research that is currently being undertaken. The patent is part of a wider suite of patent applications relating to the Sofra platform that have been filed by the company working in close collaboration with Hudson Institute of Medical Research.

While still in its early days, this cancer research project at a conceptual level indicates that the Sofra platform has versatile applications beyond mitigating inflammation in autoimmune and other chronic diseases, and could also be used to weaponise the immune system when faced with unchecked cancerous growth in the body.

Noxopharm CEO Dr Gisela Mautner said: "The development of medicines that use the body's own defences to battle cancer has led to significant breakthroughs in recent years, creating some of the world's bestselling drugs. The global [immuno-oncology market](#) is already sizeable at around US\$36 billion, and is expected to grow by 16% a year to around US\$88 billion by 2030 as the innovation pipeline continues to produce results.

"The granting of our first US patent is a major milestone for the Sofra platform, and we will continue to develop its cancer-related potential in the months ahead along with our research focusing on reducing inflammation in various diseases like lupus and rheumatoid arthritis.

"Our efforts in this space are being led with [SOF-SKN™](#), a first-in-class drug which has already advanced to the clinical trial stage."

-ENDS-

For personal use only

About the Sofra technology platform

Developed from a [breakthrough discovery](#) in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines.

[Sofra technology](#) has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US\$163.2 billion in 2024 and is expected to reach US\$219.6 billion by 2035, while the worldwide immuno-oncology market was US\$43 billion in 2023 and is projected to hit US\$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease. In essence, the Sofra technology for autoimmune diseases replicates what is naturally occurring in the bodies of healthy people, but is either absent or too little in patients with autoimmune conditions.

Further information and animations: [SOF-SKN](#) / [SOF-VAC](#)

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will”

or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

For personal use only